Based on our results, in Poland, we use a panel of founder mutations in BRCA1, BRCA2, CHEK2, and PALB2 as an initial screening tool for all patients with breast cancer and unaffected individuals with a positive family history of breast cancer. Here, CHEK2 is linked to breast carcinoma.